Skip to main content
Year archive

N4 PHARMA PLC — 2019 filings

All 113 regulatory filings released by N4 PHARMA PLC (N4P) in 2019, sourced directly from the official regulator.

113 Filings
2019 Period
2019 filings (113)
Filing Released Lang
Investor presentation
Report Publication Announcement
2019-12-17 English
Half-year Report
Earnings Release H1 2019
2019-12-17 English
MOU with The University of Dundee
Regulatory Filings
2019-12-05 English
Notice of Results
Report Publication Announcement
2019-12-04 English
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification
2019-11-28 English
Verona Pharma plc: Grant of Options to PDMR
Director's Dealing
2019-11-27 English
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
Director's Dealing
2019-11-18 English
Holding(s) in Company
Major Shareholding Notification
2019-11-14 English
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
Director's Dealing
2019-11-14 English
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference
Regulatory Filings
2019-11-13 English
SAS study clarification
Regulatory Filings
2019-11-11 English
SFX-01 results in SAS study
Earnings Release FY 2019
2019-11-11 English
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
Report Publication Announcement
2019-11-11 English
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
Earnings Release 9M 2019
2019-11-05 English
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
Report Publication Announcement
2019-10-29 English
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
Regulatory Filings
2019-10-17 English
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
Regulatory Filings
2019-10-15 English
ESMO presentation of Phase II STEM clinical data
Regulatory Filings
2019-09-30 English
Update on extended-use phase of STEM trial
Legal Proceedings Report
2019-09-23 English
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
Regulatory Filings
2019-09-19 English
Interim Results
Interim / Quarterly Report H1 2019
2019-09-18 English
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification
2019-09-09 English
Agreement for supply of SFX-01 for autism trial
M&A Activity
2019-09-05 English
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Regulatory Filings
2019-09-03 English
Update on SAS study
Legal Proceedings Report
2019-08-28 English
Results of University of Queensland Study
Regulatory Filings
2019-08-20 English
Holding(s) in Company
Major Shareholding Notification
2019-08-13 English
Verona Pharma plc: PDMR Dealing
Director's Dealing
2019-08-09 English
Grant of further European patent
Regulatory Filings
2019-08-07 English
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
Earnings Release H1 2019
2019-08-06 English
Research collaboration
Regulatory Filings
2019-08-05 English
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
Earnings Release Q2 2019
2019-08-05 English
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
Report Publication Announcement
2019-07-30 English
Grant of Options
Remuneration Information
2019-07-25 English
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
Report Publication Announcement
2019-07-24 English
Result of AGM
AGM Information
2019-07-18 English
AGM Statement
AGM Information
2019-07-18 English
Second Price Monitoring Extn
Regulatory Filings
2019-07-15 English
Price Monitoring Extension
Regulatory Filings
2019-07-15 English
Second Price Monitoring Extn
Transaction in Own Shares
2019-07-03 English
Price Monitoring Extension
Regulatory Filings
2019-07-03 English
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
Board/Management Information
2019-06-25 English
SFX-01 featured in SAH review paper
Regulatory Filings
2019-06-24 English
Result of AGM
AGM Information
2019-06-19 English
Posting of Annual Report and AGM Notice
Report Publication Announcement
2019-06-19 English
AGM Statement
AGM Information
2019-06-19 English
Second Price Monitoring Extn
Regulatory Filings
2019-06-14 English
Price Monitoring Extension
Regulatory Filings
2019-06-14 English
Full Year Results
Earnings Release FY 2019
2019-06-13 English
Notification of Preliminary Results
Regulatory Filings
2019-06-11 English
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
Regulatory Filings
2019-06-04 English
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
Report Publication Announcement
2019-05-30 English
PDMR Dealing
Director's Dealing
2019-05-29 English
Change to Director Shareholding
Director's Dealing
2019-05-28 English
Holding(s) in Company
Major Shareholding Notification
2019-05-22 English
Posting of Annual Report and Notice of AGM
Regulatory Filings
2019-05-22 English
Board Changes
Board/Management Information
2019-05-21 English
Share Option Exercise and Issue of Equity
Regulatory Filings
2019-05-21 English
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
Regulatory Filings
2019-05-20 English
Final Results
Annual Report FY 2018
2019-05-14 English
Holding(s) in Company
Major Shareholding Notification
2019-05-09 English
Holding(s) in Company
Major Shareholding Notification
2019-05-09 English
Result of GM and Completion of Placing
AGM Information
2019-05-08 English
Result of AGM
AGM Information
2019-05-07 English
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
Interim / Quarterly Report Q1 2019
2019-05-07 English
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
Regulatory Filings
2019-05-07 English
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
Report Publication Announcement
2019-05-01 English
Second Price Monitoring Extn
Regulatory Filings
2019-04-26 English
Price Monitoring Extension
Regulatory Filings
2019-04-26 English
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
Regulatory Filings
2019-04-25 English
Holding(s) in Company
Major Shareholding Notification
2019-04-24 English
Holding(s) in Company
Major Shareholding Notification
2019-04-24 English
Second Price Monitoring Extn
Regulatory Filings
2019-04-23 English
Price Monitoring Extension
Regulatory Filings
2019-04-23 English
Holding(s) in Company
Major Shareholding Notification
2019-04-23 English
Posting of Circular and Timing of General Meeting
Regulatory Filings
2019-04-18 English
Placing and Notice of General Meeting
Capital/Financing Update
2019-04-17 English
Nuvec® Research update
Legal Proceedings Report
2019-04-15 English
Director/PDMR Shareholding
Director's Dealing
2019-04-10 English
Nuvec® Research update
Regulatory Filings
2019-04-09 English
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
Regulatory Filings
2019-04-09 English
Grant of Options and RSUs and PDMR Dealings
Director's Dealing
2019-04-04 English
finnCap publishes initiation research
Report Publication Announcement
2019-04-02 English
Poster presentation of Imperial College data
Environmental & Social Information
2019-03-28 English
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
Regulatory Filings
2019-03-26 English
SFX-01 meets primary endpoints in STEM trial
Earnings Release Q1 2019
2019-03-25 English
PDMR Dealing
Director's Dealing
2019-03-25 English
2018 Annual Report and Accounts and Notice of AGM 
Report Publication Announcement
2019-03-22 English
Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
Board/Management Information
2019-03-21 English
Holding(s) in Company
Major Shareholding Notification
2019-03-20 English
Holding(s) in Company
Major Shareholding Notification
2019-03-20 English
PDMR Dealing
Director's Dealing
2019-03-20 English
Price Monitoring Extension
Regulatory Filings
2019-03-18 English
Update on SFX-01 trial read-out dates
Earnings Release Q1 2019
2019-03-18 English
PDMR Dealing
Director's Dealing
2019-03-11 English
PDMR Dealing
Director's Dealing
2019-03-07 English
PDMR Dealing
Director's Dealing
2019-03-05 English
SFX-01 data published in peer reviewed journal
Earnings Release FY 2019
2019-03-05 English
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
Regulatory Filings
2019-03-04 English
Total Voting Rights
Regulatory Filings
2019-02-28 English
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
Report Publication Announcement
2019-02-28 English
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
Report Publication Announcement FY 2018
2019-02-26 English
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
Report Publication Announcement
2019-02-20 English
Holding(s) in Company
Major Shareholding Notification
2019-02-14 English
Placing to raise £1.05 million
Share Issue/Capital Change
2019-02-08 English
Holding(s) in Company
Major Shareholding Notification
2019-02-06 English
Clinical trial update confirms read-outs on track
Regulatory Filings
2019-02-05 English
Verona Pharma to Present at Upcoming Investor Conferences
Regulatory Filings
2019-02-04 English
Grant of Options
Remuneration Information
2019-01-30 English
SFX-01 featured in Nature Reviews Drug Discovery
Regulatory Filings
2019-01-23 English
Change of Adviser
Regulatory Filings
2019-01-22 English
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
Earnings Release Q1 2019
2019-01-14 English
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
Regulatory Filings
2019-01-09 English